Home The Word Brain	My Amedeo FAQ Privacy About
	CC Journal Club Our weekly journal club for junior residents and medical students

Malignant Melanoma

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 24 articles: HTML format

Single Articles

March 2025
1. HOSSAIN SM, Gimenez G, Stockwell P, Weeks R, et al
   Pre-treatment DNA methylome and transcriptome profiles correlate with melanoma response to anti-PD1 immunotherapy.
   Cancer Lett. 2025 Mar 13:217638. doi: 10.1016/j.canlet.2025.217638.
   PubMed     Abstract available
   
   
   
2. UHER O, Hadrava Vanova K, Labitt R, Petrlakova K, et al
   Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models.
   Cancer Lett. 2025;612:217464.
   PubMed     Abstract available
   
   
   February 2025
3. MARRANCI A, Maresca L, Lodovichi S, Luserna di Rora AG, et al
   PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research.
   Cancer Lett. 2025 Feb 28:217599. doi: 10.1016/j.canlet.2025.217599.
   PubMed     Abstract available
   
   
   
4. URZI O, Olofsson Bagge R, Crescitelli R
   Extracellular vesicles in uveal melanoma - biological roles and diagnostic value.
   Cancer Lett. 2025 Feb 4:217531. doi: 10.1016/j.canlet.2025.217531.
   PubMed     Abstract available
   
   
   November 2024
5. TRAPPETTI V, Fernandez-Palomo C, Arora P, Potez M, et al
   "Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams".
   Cancer Lett. 2024 Nov 13:217326. doi: 10.1016/j.canlet.2024.217326.
   PubMed     Abstract available
   
   
   August 2024
6. GAO Q, Li N, Pan Y, Chu P, et al
   Hepatocyte growth factor promotes melanoma metastasis through ubiquitin-specific peptidase 22-mediated integrins upregulation.
   Cancer Lett. 2024 Aug 31:217196. doi: 10.1016/j.canlet.2024.217196.
   PubMed     Abstract available
   
   
   
7. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
   Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
   Cancer Lett. 2024;596:217001.
   PubMed     Abstract available
   
   
   
8. KIM YJ, Lee M, Kim EH, Lee S, et al
   Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
   Cancer Lett. 2024;596:216998.
   PubMed     Abstract available
   
   
   July 2024
9. LIU M, Zhao Z, Wang C, Sang S, et al
   Harnessing genetic interactions for prediction of immune checkpoint inhibitors response signature in cancer cells.
   Cancer Lett. 2024;594:216991.
   PubMed     Abstract available
   
   
   
10. FU Z, Zhang L, Chen R, Zhan J, et al
    Biphasic co-detection of melanoma aneuploid tumor cells and tumor endothelial cells in guidance of specifying the field cancerized surgical excision margin and administering immunotherapy.
    Cancer Lett. 2024;598:217099.
    PubMed     Abstract available
    
    
    June 2024
11. ZHANG X, Cui X, Li P, Zhao Y, et al
    EGC enhances tumor antigen presentation and CD8(+) T cell-mediated antitumor immunity via targeting oncoprotein SND1.
    Cancer Lett. 2024;592:216934.
    PubMed     Abstract available
    
    
    
12. LIAO Q, Shi H, Yang J, Ge S, et al
    FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors.
    Cancer Lett. 2024;592:216911.
    PubMed     Abstract available
    
    
    May 2024
13. WANG J, Hirose H, Du G, Chong K, et al
    Corrigendum to "P-REX1 amplification promotes progression of cutaneous melanomavia the PAK1/P38/MMP-2 pathway" [Cancer Lett. 407 (2017) 66-75].
    Cancer Lett. 2024 May 23:216966. doi: 10.1016/j.canlet.2024.216966.
    PubMed    
    
    
    April 2024
14. JIA Y, Zhang F, Meng X, Andreev D, et al
    Osteocytes support bone metastasis of melanoma cells by CXCL5.
    Cancer Lett. 2024 Apr 6:216866. doi: 10.1016/j.canlet.2024.216866.
    PubMed     Abstract available
    
    
    
15. WANG L, Liu X, Han Y, Tsai HI, et al
    TRAF6 enhances PD-L1 expression through YAP1-TFCP2 signaling in melanoma.
    Cancer Lett. 2024 Apr 5:216861. doi: 10.1016/j.canlet.2024.216861.
    PubMed     Abstract available
    
    
    February 2024
16. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    Retraction notice to "The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model" [Cancer Lett. 419 (2018) 30-39].
    Cancer Lett. 2024 Feb 2:216670. doi: 10.1016/j.canlet.2024.216670.
    PubMed     Abstract available
    
    
    January 2024
17. ZHANG J, Joshua AM, Yue L, O'Meara CH, et al
    Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma.
    Cancer Lett. 2024 Jan 26:216633. doi: 10.1016/j.canlet.2024.216633.
    PubMed     Abstract available
    
    
    
18. LIU C, Cheng X, Han K, Hong L, et al
    A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study.
    Cancer Lett. 2024 Jan 19:216663. doi: 10.1016/j.canlet.2024.216663.
    PubMed     Abstract available
    
    
    November 2023
19. CERDIDO S, Abrisqueta M, Sanchez-Beltran J, Lambertos A, et al
    MGRN1 depletion promotes intercellular adhesion in melanoma by upregulation of E-cadherin and inhibition of CDC42.
    Cancer Lett. 2023;581:216484.
    PubMed     Abstract available
    
    
    
20. HU X, Hu Z, Zhang H, Zhang N, et al
    Deciphering the tumor-suppressive role of PSMB9 in melanoma through multi-omics and single-cell transcriptome analyses.
    Cancer Lett. 2023 Nov 7:216466. doi: 10.1016/j.canlet.2023.216466.
    PubMed     Abstract available
    
    
    September 2023
21. XU M, Li S
    Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.
    Cancer Lett. 2023 Sep 18:216397. doi: 10.1016/j.canlet.2023.216397.
    PubMed     Abstract available
    
    
    July 2023
22. ZHANG X, Hu Z, Wang X, Li L, et al
    Corrigendum to "ANXA10 promotes melanoma metastasis by suppressing E3 ligase TRIM41-directed PKD1 degradation" [Cancer Lett. 519 (2021) 237-249].
    Cancer Lett. 2023 Jul 18:216310. doi: 10.1016/j.canlet.2023.216310.
    PubMed    
    
    
    April 2023
23. ZHAN D, Zheng N, Zhao B, Cheng F, et al
    Expanding individualized therapeutic options via genoproteomics.
    Cancer Lett. 2023;560:216123.
    PubMed     Abstract available
    
    
    March 2023
24. ZHAO J, Gao N, Xu J, Zhu X, et al
    Novel strategies in melanoma treatment using silver nanoparticles.
    Cancer Lett. 2023 Mar 27:216148. doi: 10.1016/j.canlet.2023.216148.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.